This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Philanthropist Bill Gates announced Thursday that he will wind down his massive charity in 20 years, doubling spending over that time to accelerate the work it hopes to achieve. Gates made the announcement on the 25th anniversary of the launch of the Gates Foundation, the third-largest player in international philanthropy. He said the foundation would spend $200 billion between now and 2045, when its operations will wind down.
As a primary care physician serving Medicaid patients, I recently witnessed a preventable hospitalization that perfectly illustrates America’s health care dysfunction. My homebound patient with heart failure needed a routine lab test to adjust their medication. While commercially insured patients can access electronic lab orders, my patient’s Medicaid plan contracted exclusively with a laboratory requiring physical forms by mail.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pager Health, a virtual care navigation platform, sees opportunities to use generative AI to help guide health plan members and provide a more personalized experience, like a companion to provide one-on-one support.
A new shareholder lawsuit claims that UnitedHealth Group made misleading statements about its financial outlook following the murder of a prominent company executive.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
As EU Health Ministries approach the final stages of negotiations on the future of Europes pharmaceutical rules, Medicines for Europe has called for key actions to ensure medicine supply is protected in the region. Alongside other actions, the organisation proposed that health is central to all political decisions and to conclude the EU pharmaceutical reform.
The Ensuring Community Access to Pharmacist Services (ECAPS) Act would enhance Medicare coverage for pharmacist services and ensure seniors can access essential care in underserved areas.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
A global survey by Johnson & Johnson MedTech has revealed that a majority of Europeans are willing to share their health data in exchange for more personalised care signalling growing public trust in the role of technology in healthcare. Conducted between August and September 2024, the survey gathered responses from both the general public […] The post Majority of Europeans trust technology to improve healthcare, Johnson & Johnson survey finds appeared first on Pharmafile.
Necrotizing enterocolitis (NEC) is a life-threatening illness that is characterized by the inflammation of the intestinal lining, which can lead to intestinal perforation.
With this approval, avutometinib/defactinib has become the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Startup Kouper spent the past three years working on this problem, taking a tech-based approach that uses generative AI to ensure that patients don't fall through the cracks after discharge.
Top-line results from two pivotal Phase III trials found that MR-107A-02 significantly reduced pain intensity following herniorrhaphy and bunionectomy surgeries compared to placebo.
The track-and-trace systems provider expands its life sciences portfolio by integrating the high-speed, adaptable ETF-300 precision labeler through a partnership that brings Industry 4.0-ready capabilities, advanced printing tech, and enhanced data security to pharmaceutical packaging.
Founder and CEO of Alume Biosciences, Quyen Nguyen, MD, PhD, discusses nerve regeneration, nerve visualization and the reason behind what she does at Alume Biosciences.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
135 
Let's personalize your content